Hong Kong pharmaceutical stocks fell on Wednesday after US President Donald Trump said his administration would soon implement "a major tariff on pharmaceuticals" from foreign nations.
Trump made the remarks at a Republican event, suggesting the move will force drug companies to relocate their operations to the US, according to a USA Today report.
While initially sparing pharmaceuticals from recent tariffs, Trump has indicated for months that the imported drug industry is a future target, the report said.
The news sent shares of Hong Kong-listed drugmakers falling on Wednesday afternoon.
Alphamab Oncology (HKG:9966) led the decliners with an almost 6% fall, followed by Boan Biotech (HKG:6955) with a 5% drop. Luye Pharma (HKG:2186) slid 4.4%, while BeiGene (HKG:6160) and Genscript Bio (HKG:1548) retreated nearly 4%. Zai Lab (HKG:9688) slipped 3%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。